VB0 Stock Overview
An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Viva Biotech Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.10 |
| 52 Week High | HK$0.13 |
| 52 Week Low | HK$0.044 |
| Beta | 1.19 |
| 1 Month Change | 4.08% |
| 3 Month Change | 54.55% |
| 1 Year Change | -3.77% |
| 3 Year Change | -79.60% |
| 5 Year Change | -79.31% |
| Change since IPO | -80.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| VB0 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -2.8% | -2.6% |
| 1Y | -3.8% | -5.9% | 6.9% |
Return vs Industry: VB0 exceeded the German Life Sciences industry which returned -5.9% over the past year.
Return vs Market: VB0 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| VB0 volatility | |
|---|---|
| VB0 Average Weekly Movement | 12.9% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VB0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: VB0's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 2,043 | Chen Cheney Mao | www.vivabiotech.com.cn |
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies.
Viva Biotech Holdings Fundamentals Summary
| VB0 fundamental statistics | |
|---|---|
| Market cap | €226.89m |
| Earnings (TTM) | -€41.77k |
| Revenue (TTM) | €262.09m |
0.9x
P/S Ratio-5,432x
P/E RatioIs VB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VB0 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.00b |
| Cost of Revenue | CN¥1.32b |
| Gross Profit | CN¥671.61m |
| Other Expenses | CN¥671.93m |
| Earnings | -CN¥318.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00015 |
| Gross Margin | 33.66% |
| Net Profit Margin | -0.016% |
| Debt/Equity Ratio | 39.8% |
How did VB0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 13:36 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Viva Biotech Holdings is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Chak Yuen | BOCI Research Ltd. |
| Dennis Ip | Daiwa Securities Co. Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |